Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

Haematologica

Volumn 99, Issue 1, 2014, Pages 37-45

  Brecqueville, Mandy ^a,b,c   Rey, Jérôme ^a,b,c   Devillier, Raynier ^a,b,c   Guille, Arnaud ^a,b   Gillet, Rémi ^a,b,c   Adélaide, José ^a,b   Gelsi Boyer, Véronique ^a,b,c   Arnoulet, Christine ^a,b   Chaffanet, Max ^a,b,c   Mozziconacci, Marie Joelle ^a,b,c   Vey, Norbert ^a,b,c   Birnbaum, Daniel ^a,b,c   Murati, Anne ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84892610757     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.091454     Document Type: Article

References (50)

1. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009; 115(17):3842-3847.
2. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737-740.
3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
4. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010; 115(9):1703-1708.
5. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.
6. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. 2009;82(5):329-338.
7. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009;113(18):4171-4178.
8. James C, Ugo V, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;21(6-7):669-670.
9. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
10. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uni-parental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
11. Delhommeau F, James C, Trannoy S, Massé A, Kosmider O, Pharm D, et al. Mutation in TET2 in Myeloid Cancers. New Engl J Med. 2009;360(22):2289-2301.
12. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélaïde J, Rey J, et al. Mutations of ASXL1 gene in myeloprolifer-ative neoplasms. Leukemia. 2009;23(11): 2183-2186.
13. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, Tefferi A. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24(6):1146-1151.
14. Jäger R, Gisslinger H, Passamonti F, Rumi E, Berg T, Gisslinger B, et al. Deletions of the transcription factor Ikaros in myeloprolifer-ative neoplasms. Leukemia. 2010;24(7): 1290-1298.
15. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myelo-proliferative neoplasms. Blood. 2010;116 (6):988-992.
16. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
17. Brecqueville M, Cervera N, Adélaïde J, Rey J, Carbuccia N, Chaffanet M, et al. Mutations and deletions of the SUZ12 poly- comb gene in myeloproliferative neoplasms. Blood Cancer J. 2011;1(8):e33.
18. Brecqueville M, Cervera N, Gelsi-Boyer V, Murati A, Adélaïde J, Chaffanet M, et al. Rare mutations in DNMT3A in myeloprolifera-tive neoplasms and myelodysplastic syndromes. Blood Cancer J. 2011;1(5):e18.
19. Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2012; 26(5):1135-1157.
20. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168-4171.
21. Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, et al. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011;96 (10):1462-1469.
22. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25(7):1200-1202.
23. Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, et al. Mutation Analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in Myeloproliferative Neoplasms. Genes Chromosomes Cancer. 2012;51(8): 743-755.
24. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofi-brosis with myeloid metaplasia. Br J Haematol. 2001;113(3):763-771.
25. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19): 5227-5234.
26. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, Knudson RA, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012;26(3):475-480.
27. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013. In press.
28. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008. Revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
29. Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151(4):365-375.
30. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocyt-ic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148-150.
31. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 2006;107(12):4589-4596.
32. Vannucchi AM, Bianchi L, Paoletti F, Pancrazzi A, Torre E, Nishikawa M, et al. A pathobiologic pathway linking thrombopoi-etin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood. 2005;105(9):3493-3501.
33. Gui T, Sun Y, Gai Z, Shimokado A, Muragaki Y, Zhou G. The loss of Trps1 suppresses ureteric bud branching because of the activation of TGF-signaling. Dev Biol. 2013;377(2):415-427.
34. Plo I, Nakatake M, Malivert L, De Villartay J-P, Giraudier S, Villeval J-L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008;112(4):1402-1412.
35. Shikauchi Y, Saiura A, Kubo T, Niwa Y, Yamamoto J, Murase Y, et al. SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepato-cellular carcinoma. Mol Cell Biol. 2009;29(7):1944-1958.
36. Brecqueville M, Adélaïde J, Bertucci F, Finetti P, Chaffanet M, Murati A. Alterations of polycomb gene BMI1 in human myelopro-liferative neoplasms. Cell Cycle. 2012;11(16):3141-3142.
37. Oguro H, Yuan J, Tanaka S, Miyagi S, Mochizuki-Kashio M, Ichikawa H, et al. Lethal myelofibrosis induced by Bmi1-defi-cient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J Exp Med. 2012;209(3):445-454.
38. Merker JD, Roskin KM, Ng D, Pan C, Fisk DG, King JJ, et al. Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and nonrecurrent candidate genes. Haematologica. 2013. In press.
39. Schaub FX, Jäger R, Looser R, Hao-Shen H, Hermouet S, Girodon F, et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009;113(9):2022-2027.
40. Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C, et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked throm-bocytosis strengthen the assignment to the category of myelodysplastic/myeloprolifera-tive neoplasms. Haematologica. 2013;98 (2):e15-e17.
41. Hahm C, Mun YC, Seong CM, Chung WS, Huh J. Additional genomic aberrations identified by single nucleotide polymorphism array-based karyotyping in an acute myeloid leukemia case with isolated del(20q) abnormality. Ann Lab Med. 2012;32(6):445-449.
42. Braun T, De Botton S, Taksin A-L, Park S, Beyne-Rauzy O, Coiteux V, et al. Characteristics and outcome of myelodys-plastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res. 2011;35(7):863-867.
43. Aziz A, Baxter EJ, Edwards C, Cheong CY, Ito M, Bench A, et al. Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. J Clin Invest. 2012;123(5):2169-2182.
44. Valleron W, Laprevotte E, Gautier E-F, Quelen C, Demur C, Delabesse E, et al. Specific small nucleolar RNA expression profiles in acute leukemia. Leukemia. 2012;26(9):2052-2060.
45. Boudry-Labis E, Roche-Lestienne C, Nibourel O, Boissel N, Terre C, Perot C, et al. Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia. Am J Hematol. 2013;88(4):306-311.
46. Wall M, Rayeroux KC. ETV6 deletion is a common additional abnormality in patients with myelodysplastic syndromes or acute myeloid leukemia and monosomy 7. Haematologica. 2012;97(12):1931-1933.
47. Andreasson P, Johansson B, Arheden K, Billström R, Mitelman F, Höglund M. Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities. Genes Chromosomes Cancer. 1997;19(2):77-83.
48. Haferlach C, Bacher U, Schnittger S, Alpermann T, Zenger M. ETV6 Rearrangements Are Recurrent in Myeloid Malignancies and Are Frequently Associated with Other Genetic Events. Genes Chromosomes Cancer. 2012;51(4):328-337.
49. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29(18):2499-2506.
50. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013;27(1):82-91.